Professor Tony Cunningham AO is Executive Director, The Westmead Institute for Medical Research and Director of the Institute’s Centre for Virus Research, Professor of Research Medicine and Sub-Dean (Research) Sydney Medical School, Westmead , the University of Sydney. Since 2003 he has been Director of the Australian Centre for HIV and Hepatitis Virology Research (ACH2), funded directly by the Australian Government.
He is a clinician scientist who trained in infectious diseases, clinical virology and virology research at the University of Melbourne and as a postdoctoral fellow in infectious diseases at Stanford University. His major research interests are in HIV and Herpesviruses (mainly Herpes simplex virus) biology and immunology, especially in relation to the development of vaccines and microbicides. He has published more than 380 papers in various journals or books on these topics and has been cited more than 12,000 times.
He has also played a leading international role in elucidating HIV interactions with macrophages, as reservoirs, and with dendritic cells as an initial target cell in the anogenital mucosa. His group has also made numerous key contributions to HSV immunology which has led to the development and trialling of a partially successful HSV vaccine candidate and recently a highly efficacious vaccine against Herpes zoster by GlaxoSmithKline.
He has participated in numerous international roundtables and consults for three global or national vaccine companies.
In 2010, Tony was made an Officer in the Order of Australia (AO) for “service to medicine, particularly in the field of viral research and through the development and leadership of medical and biomedical research” and, in 2015, he was elected a fellow of the Australian Academy of Health and Medical Sciences (FAHMS). He is also President of The Association of Australian Medical Research Institutes (AAMRI).